FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Woods AC, Norsworthy KJ, Choe M, Gehrke BJ, Chen H, Vallejo J, Pan L, Jiang X, Li H, Kraft J, Liu J, Charlab R, Okusanya OO, Booth B, Pazdur R, Theoret MR, de Claro RA.
Woods AC, et al.
Clin Cancer Res. 2024 Oct 30. doi: 10.1158/1078-0432.CCR-24-2196. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39475462